OriCell Re-Novo Capsule
OriCell Re-Novo Capsule : Product registered in Malaysia. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.
NPRA, Malaysian pharmaceutical products register, retrieved 27 October 2026.
Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0
The foreign register category does not determine the regulatory category of the product in France.
French and European references for recognised ingredients
No point flagged by the rules applied to recognised ingredients.
Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.
Published composition
| Published ingredient | Published text and quantity | Identified nutrient or substance |
|---|---|---|
| Cordyceps sinensis | Cordyceps sinensis[150 mg,480 mg] | Not identified |
| Arctostaphylos uva ursi | Arctostaphylos uva ursi[60 mg,480 mg] | Not identified |
| Apium graveolens | Apium graveolens[30 mg,480 mg] | Not identified |
| Vaccinium macrocarpon | Vaccinium macrocarpon[50 mg,480 mg] | Not identified |
| Phyllanthus niruri | Phyllanthus niruri[30 mg,480 mg] | Not identified |
| Vaccinium uliginosum | Vaccinium uliginosum[30 mg,480 mg] | Not identified |
| Poria cocos | Poria cocos[20 mg,480 mg] | Not identified |
| Eucommia ulmoides | Eucommia ulmoides[20 mg,480 mg] | Not identified |
| Panax ginseng (Rubra) | Panax ginseng (Rubra)[10 mg,480 mg] | Not identified |
The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.
Product record
- Registration number
- MAL25086196T
- Type
- Natural product
- Published status
- PRODUCT APPROVED
- Licence holder
- EXCEL HERBAL INDUSTRIES SDN. BHD.
- Manufacturer
- EXCEL HERBAL INDUSTRIES SDN. BHD.
- Registration period starting
- 2025-08-07
- Published validity end
- 2030-08-07
Original register data
View published fields and their variants
- Active ingredients
- Cordyceps sinensis[150 mg,480 mg],Arctostaphylos uva ursi[60 mg,480 mg],Apium graveolens[30 mg,480 mg],Vaccinium macrocarpon[50 mg,480 mg],Phyllanthus niruri[30 mg,480 mg],Vaccinium uliginosum[30 mg,480 mg],Poria cocos[20 mg,480 mg],Eucommia ulmoides[20 mg,480 mg],Panax ginseng (Rubra)[10 mg,480 mg]
- Valid until
- 2030-08-07
- Registration date
- 2025-08-07
- Published description
- NATURAL PRODUCT
- Licence holder
- EXCEL HERBAL INDUSTRIES SDN. BHD.
- Producer
- EXCEL HERBAL INDUSTRIES SDN. BHD.
- Published name
- OriCell Re-Novo Capsule
- Published reference
- 2025010617150T
- Registration number
- MAL25086196T
- Published status
- PRODUCT APPROVED
Official source
View the official register, number MAL25086196T
Ministry of Health Malaysia / NPRA, Pharmaceutical Products, CC BY 4.0
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vaccinium macrocarpon
Read the warning, when it applies and the studies cited
CRANBERRY - VACCINIUM MACROCARPON
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
DRIED CRANBERRY JUICE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a history of kidney stones (Gettman et al. 2005; Terris et al. 2001).
Sources cited by Health Canada (2)
- Gettman MT, Ogan K, Brinkley LJ, Adams-Huet B, Pak CYC, Pearle MS. Effect of cranberry juice consumption on urinary stone risk factors. The Journal of Urology 2005;174(2):590-594. PubMed Randomised trial
- Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57(1):26-29. PubMed
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Brinker 2010; Aston et al. 2006; Rindone and Murphy 2005; Grant 2004).
Sources cited by Health Canada (4)
- Aston JL, Lodolce AE, Shapiro NL. Interaction between warfarin and cranberry juice. Pharmacotherapy 2006;26(9):1314-1319. PubMed
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Grant P. Warfarin and cranberry juice: an interaction? The Journal of Heart Valve Disease 2004;13(1):25-26. PubMed Case report
- Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. American Journal of Therapeutics 2005;13(3):283-284.
Condition of application: (Recurrent) urinary tract infection.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “OriCell Re-Novo Capsule”, https://compoatlas.com/en/supplements/malaysia/MAL25086196T-oricell-re-novo-capsule, updated 27 October 2026.